[{"orgOrder":0,"company":"Instituto do Cancer do Estado de S\u00e3o Paulo","sponsor":"Libbs Farmaceutica","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||26S proteasome","graph1":"Oncology","graph2":"Phase II","graph3":"Instituto do Cancer do Estado de S\u00e3o Paulo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrathecal","sponsorNew":"Instituto do Cancer do Estado de S\u00e3o Paulo \/ Libbs Farmaceutica","highestDevelopmentStatusID":"8","companyTruncated":"Instituto do Cancer do Estado de S\u00e3o Paulo \/ Libbs Farmaceutica"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA receptor\/Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Venus Remedies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"GLAND PHARMA LIMITED","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GLAND PHARMA LIMITED \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GLAND PHARMA LIMITED \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Birtamimab","moa":"||Light chain aggregates","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Birtamimab","moa":"||Light chain aggregate","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Birtamimab","moa":"||Light chain aggregate","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Prothena \/ Jefferies"},{"orgOrder":0,"company":"Caelum Biosciences","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Caelum Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caelum Biosciences \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Caelum Biosciences \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Caelum Biosciences","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Caelum Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caelum Biosciences \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Caelum Biosciences \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Caelum Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Bortezomib","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Caelum Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caelum Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Caelum Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Caelum Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Bortezomib","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Caelum Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caelum Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Caelum Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fortress Biotech \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Fortress Biotech \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"Bortezomib","moa":"||B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Morgan Stanley"},{"orgOrder":0,"company":"PETHEMA Foundation","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Autologous Stem Cell Transplant","moa":"||Tumor necrosis factor receptor superfamily member 17 | Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"PETHEMA Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"PETHEMA Foundation \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"PETHEMA Foundation \/ GSK"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Hellenic Society of Hematology","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase II","graph3":"Hellenic Society of Hematology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Hellenic Society of Hematology \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Hellenic Society of Hematology \/ Sanofi"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Tanja Andrea Gruber","sponsor":"Pediatric Oncology ETIC | Amgen Inc | Lucile Packard Foundation for Children's Health | Kura Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tanja Andrea Gruber","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Tanja Andrea Gruber \/ Pediatric Oncology ETIC | Amgen Inc | Lucile Packard Foundation for Children's Health | Kura Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Tanja Andrea Gruber \/ Pediatric Oncology ETIC | Amgen Inc | Lucile Packard Foundation for Children's Health | Kura Oncology"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Healthwell Acquisition Corp. I","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Termination","leadProduct":"Lenalidomide","moa":"||Cereblon","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Starton Therapeutics \/ Healthwell Acquisition Corp. I","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Healthwell Acquisition Corp. I"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"||Cereblon","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"||Cereblon","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"||Cereblon","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||growth factors: tumor necrosis factors; Fc fusion protein","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Cyclic ADP-ribose hydrolase 1 (CD38)","graph1":"Oncology","graph2":"Phase I","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Methotrexate","moa":"||Dihydrofolate reductase","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mezigdomide","moa":"||thalidomide derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Ida Bruun Kristensen","sponsor":"Karyopharm Therapeutics | Odense Patient Data Explorative Network","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Selinexor","moa":"||Exportin-1","graph1":"Oncology","graph2":"Phase II","graph3":"Ida Bruun Kristensen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ida Bruun Kristensen \/ Karyopharm Therapeutics | Odense Patient Data Explorative Network","highestDevelopmentStatusID":"8","companyTruncated":"Ida Bruun Kristensen \/ Karyopharm Therapeutics | Odense Patient Data Explorative Network"},{"orgOrder":0,"company":"Canadian Myeloma Research Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Iberdomide","moa":"||CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Canadian Myeloma Research Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Canadian Myeloma Research Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Canadian Myeloma Research Group \/ Inapplicable"},{"orgOrder":0,"company":"Xia Zhongjun","sponsor":"Antengene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||Exportin-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xia Zhongjun","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xia Zhongjun \/ Antengene","highestDevelopmentStatusID":"7","companyTruncated":"Xia Zhongjun \/ Antengene"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Shilpa Medicare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amneal Pharmaceuticals \/ Shilpa Medicare","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Shilpa Medicare"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||26s Proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centocor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Centocor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Centocor \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Centocor \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||26S proteasome","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Omar Nadeem, MD","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase II","graph3":"Omar Nadeem, MD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Omar Nadeem, MD \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Omar Nadeem, MD \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Stichting European Myeloma Network","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase III","graph3":"Stichting European Myeloma Network","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stichting European Myeloma Network \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Stichting European Myeloma Network \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"University of Miami","sponsor":"Amgen Inc | Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||26S proteasome","graph1":"Oncology","graph2":"Phase II","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"University of Miami \/ Amgen Inc | Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"University of Miami \/ Amgen Inc | Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||26S proteasome","graph1":"Immunology","graph2":"Undisclosed","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chinese SLE Treatment And Research Group \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Chinese SLE Treatment And Research Group \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ever Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ever Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||Tumor necrosis factor receptor superfamily member 17 | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Poitiers University Hospital","sponsor":"Intergroupe Francophone du Myelome | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase III","graph3":"Poitiers University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poitiers University Hospital \/ Intergroupe Francophone du Myelome | Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Poitiers University Hospital \/ Intergroupe Francophone du Myelome | Sanofi"},{"orgOrder":0,"company":"Stichting European Myeloma Network","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase III","graph3":"Stichting European Myeloma Network","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stichting European Myeloma Network \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Stichting European Myeloma Network \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Heidelberg University Hospital","sponsor":"Deutsche Studiengruppe Multiples Myelom | KKS Netzwerk | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase III","graph3":"Heidelberg University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heidelberg University Hospital \/ Deutsche Studiengruppe Multiples Myelom | KKS Netzwerk | Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Heidelberg University Hospital \/ Deutsche Studiengruppe Multiples Myelom | KKS Netzwerk | Sanofi"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||Tumor necrosis factor receptor superfamily member 17 | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||Tumor necrosis factor receptor superfamily member 17 | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Intergroupe Francophone du Myelome","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Tumor necrosis factor receptor superfamily member 17 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Phase III","graph3":"Intergroupe Francophone du Myelome","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intergroupe Francophone du Myelome \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Intergroupe Francophone du Myelome \/ Pfizer Inc"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Selinexor","moa":"||Exportin-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"ECOG-ACRIN Cancer Research Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||26S proteasome","graph1":"Oncology","graph2":"Phase III","graph3":"ECOG-ACRIN Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ECOG-ACRIN Cancer Research Group \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"ECOG-ACRIN Cancer Research Group \/ National Cancer Institute"},{"orgOrder":0,"company":"PETHEMA Foundation","sponsor":"Bristol Myers Squibb | Sanofi | Adknoma | Start from Scratch","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||26S proteasome","graph1":"Oncology","graph2":"Phase III","graph3":"PETHEMA Foundation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PETHEMA Foundation \/ Bristol Myers Squibb | Sanofi | Adknoma | Start from Scratch","highestDevelopmentStatusID":"10","companyTruncated":"PETHEMA Foundation \/ Bristol Myers Squibb | Sanofi | Adknoma | Start from Scratch"},{"orgOrder":0,"company":"Children's Cancer Group, China","sponsor":"Shanghai Children's Medical Center | Beijing Children's Hospital | Children's Hospital of Scow University | West China Second University Hospital | Nanjing Children's Hospital | Qilu Hospital of Shandong University | Tianjin Medical University Cancer Inst","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Prednisone","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Children's Cancer Group, China","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Cancer Group, China \/ Shanghai Children's Medical Center | Beijing Children's Hospital | Children's Hospital of Scow University | West China Second University Hospital | Nanjing Children's Hospital | Qilu Hospital of Shandong University | Tianjin Medical University Cancer Inst","highestDevelopmentStatusID":"10","companyTruncated":"Children's Cancer Group, China \/ Shanghai Children's Medical Center | Beijing Children's Hospital | Children's Hospital of Scow University | West China Second University Hospital | Nanjing Children's Hospital | Qilu Hospital of Shandong University | Tianjin Medical University Cancer Inst"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Peking Union Medical College Hospital \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Jacob Laubach","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase II","graph3":"Jacob Laubach","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jacob Laubach \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Jacob Laubach \/ Sanofi"},{"orgOrder":0,"company":"Fondazione Italiana Linfomi","sponsor":"Janssen-Cilag","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase II","graph3":"Fondazione Italiana Linfomi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fondazione Italiana Linfomi \/ Janssen-Cilag","highestDevelopmentStatusID":"8","companyTruncated":"Fondazione Italiana Linfomi \/ Janssen-Cilag"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"Nordic Myeloma Study Group | St. Olavs Hospital | Helse Stavanger","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase II","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oslo University Hospital \/ Nordic Myeloma Study Group | St. Olavs Hospital | Helse Stavanger","highestDevelopmentStatusID":"8","companyTruncated":"Oslo University Hospital \/ Nordic Myeloma Study Group | St. Olavs Hospital | Helse Stavanger"},{"orgOrder":0,"company":"Cancer Trials Ireland","sponsor":"Sanofi | Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase II","graph3":"Cancer Trials Ireland","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Trials Ireland \/ Sanofi | Dana-Farber Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Cancer Trials Ireland \/ Sanofi | Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Johnson & Johnson Innovative Medicine | Sarah Cannon","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Darzalex","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase II","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Johnson & Johnson Innovative Medicine | Sarah Cannon","highestDevelopmentStatusID":"8","companyTruncated":"University of Alabama at Birmingham \/ Johnson & Johnson Innovative Medicine | Sarah Cannon"},{"orgOrder":0,"company":"PETHEMA Foundation","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase II","graph3":"PETHEMA Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PETHEMA Foundation \/ Janssen Pharmaceutica","highestDevelopmentStatusID":"8","companyTruncated":"PETHEMA Foundation \/ Janssen Pharmaceutica"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Tumor necrosis factor receptor superfamily member 17 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Phase II","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nantes University Hospital \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Nantes University Hospital \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"North Estonia Medical Centre","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase II","graph3":"North Estonia Medical Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"North Estonia Medical Centre \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"North Estonia Medical Centre \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Johnson & Johnson Innovative Medicine | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||26S proteasome","graph1":"Oncology","graph2":"Phase II","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Johnson & Johnson Innovative Medicine | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Gabrail Cancer Center Research \/ Johnson & Johnson Innovative Medicine | National Cancer Institute"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||DNA","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Northwell Health \/ Inapplicable"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||DNA","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Northwell Health \/ Inapplicable"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Sanofi"},{"orgOrder":0,"company":"Augusta University","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase I","graph3":"Augusta University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Augusta University \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Augusta University \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Sanofi | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||26S proteasome","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Sanofi | National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Gabrail Cancer Center Research \/ Sanofi | National Cancer Institute"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mitoxantrone","moa":"||DNA topoisomerase II alpha | DNA","graph1":"Oncology","graph2":"Phase I","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CSPC Pharmaceutical Group \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals for Velcade
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
